Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
The Netherlands Cancer Institute
Xencor, Inc.
Gritstone bio, Inc.
Incyte Corporation
Hoosier Cancer Research Network
Bristol-Myers Squibb